Eleven Bio's eye drug fails another late-stage study

(Reuters) - Eleven Biotherapeutics Inc said its lead eye drug failed in a late-stage trial in treating patients with severe allergic conjunctivitis, sending its shares down 36 percent in after-market trading.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news